ERBB2 and in situ carcinoma: The results from a recent next-generation sequencing (NGS) study on CIS cases reported a rate of missense mutations in the extracellular domain of HER2 as high as 16%, encompassing the pathogenic activating S310F mutation, which is a common HER2 alteration in BC [34].